LifeStance Health Group, Inc. (NASDAQ:LFST) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 26.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,452,178 shares of the company's stock after purchasing an additional 729,794 shares during the quarter. Geode Capital Management LLC owned approximately 0.90% of LifeStance Health Group worth $24,170,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. TD Asset Management Inc purchased a new position in LifeStance Health Group in the 2nd quarter valued at about $623,000. Charles Schwab Investment Management Inc. lifted its stake in shares of LifeStance Health Group by 36.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,104,453 shares of the company's stock valued at $7,731,000 after buying an additional 297,723 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of LifeStance Health Group by 24.9% during the third quarter. Point72 Asset Management L.P. now owns 1,100,441 shares of the company's stock valued at $7,703,000 after buying an additional 219,329 shares during the period. Landscape Capital Management L.L.C. boosted its position in LifeStance Health Group by 43.7% during the third quarter. Landscape Capital Management L.L.C. now owns 367,935 shares of the company's stock worth $2,576,000 after acquiring an additional 111,894 shares during the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new stake in LifeStance Health Group in the 3rd quarter worth approximately $3,150,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on LFST shares. The Goldman Sachs Group upgraded LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $10.00 price objective on the stock in a report on Monday, December 16th. Barclays raised their price target on LifeStance Health Group from $6.00 to $7.00 and gave the stock an "underweight" rating in a research note on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $8.70.

LifeStance Health Group Trading Up 0.7 %

Shares of LFST stock traded up $0.05 on Friday, reaching $7.49. 1,234,274 shares of the stock were exchanged, compared to its average volume of 1,516,011. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19. The stock has a market cap of $2.87 billion, a P/E ratio of -28.81 and a beta of 1.28. The firm has a 50 day moving average of $7.23 and a two-hundred day moving average of $6.45. LifeStance Health Group, Inc. has a 1-year low of $4.64 and a 1-year high of $9.20.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.05. LifeStance Health Group had a negative return on equity of 6.66% and a negative net margin of 7.90%. The company had revenue of $312.70 million during the quarter, compared to analyst estimates of $302.25 million. During the same period in the prior year, the firm posted ($0.17) earnings per share. The firm's revenue was up 18.9% on a year-over-year basis. On average, research analysts anticipate that LifeStance Health Group, Inc. will post -0.2 EPS for the current year.

Insider Buying and Selling

In related news, Director Robert Bessler sold 75,000 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $7.54, for a total value of $565,500.00. Following the completion of the transaction, the director now owns 1,424,447 shares of the company's stock, valued at approximately $10,740,330.38. This represents a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 6.60% of the stock is owned by corporate insiders.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.